NCT06727812 Multicenter Phase I Study of HRS-6208 in Patients With Solid Tumors
| NCT ID | NCT06727812 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Shandong Suncadia Medicine Co., Ltd. |
| Condition | Solid Tumors |
| Study Type | INTERVENTIONAL |
| Enrollment | 206 participants |
| Start Date | 2024-12-17 |
| Primary Completion | 2027-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 206 participants in total. It began in 2024-12-17 with a primary completion date of 2027-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is an open, multicenter Phase I study to evaluate the safety and tolerability of HRS-6208 in patients with advanced solid tumors.
Eligibility Criteria
Inclusion Criteria: 1. Patients with unresectable locally advanced or metastatic solid tumors confirmed by histology or cytology who have relapsed or progressed after standard treatment, or have no standard treatment options, or do not apply standard treatment at this stage; 2. Age 18\~75 years old; 3. At least one measurable lesion per RECIST v1.1 criteria; 4. ECOG PS score: 0-1. Exclusion Criteria: 1. History of other malignancies within the past 5 years, excluding cured basal cell carcinoma of the skin and carcinoma in situ of the cervix; 2. The adverse reactions of previous anti-tumor therapy have not recovered to NCI-CTCAE v5.0 grade evaluation ≤ 1; 3. He has severe cardiovascular and cerebrovascular diseases; 4. Severe infection within 4 weeks prior to the first dose.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06727812 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Solid Tumors. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06727812 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT06727812 currently recruiting?
Yes, NCT06727812 is actively recruiting participants. Contact the research team at xin.xu@hengrui.com for enrollment information.
Where is the NCT06727812 trial being conducted?
This trial is being conducted at Nanjing, China, Chengdu, China.
Who is sponsoring the NCT06727812 clinical trial?
NCT06727812 is sponsored by Shandong Suncadia Medicine Co., Ltd.. The trial plans to enroll 206 participants.